SOURCE: IO News Wire

IO News Wire

February 03, 2010 09:15 ET

(OTC: KKUR) Leading the Way in Cancer Detection and Cure

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by the IO News Wire.

NEW YORK, NY--(Marketwire - February 3, 2010) - ChromoCure, Inc. (PINKSHEETS: KKUR) announced yesterday that they have kicked off their newest research initiative, "Project Boveri: Find the Cure."

The recent pledge made by President Obama stating that we will cure cancer "in our time" has put more attention on cancer research than ever before. ChromoCure has championed the chromosomal/aneuploidy theory of cancer which has been corroborated in recent Medical findings by third party research publications including the Mayo Clinic.

ChromoCure is reaching out to collaborate with others to expand its research into detecting cancer in its earliest stages, greatly aiding the ability to cure it. ChromoCure, and its proprietary ChromoSomal detection technology can detect cancer 100% of the time at every stage of cancer development.

For more information, please visit:

Other active stocks are International Stem Cell Corp (OTCBB: ISCO) MedCath Corp (NASDAQ: MDTH) and Select Medical Holdings (NYSE: SEM)

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO News Wire twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.

Contact Information